Tuesday, February 21, 2012
Actos Side Effects – Risk of Bladder Cancer
Actos, a prescription drug used to control blood sugar levels in type 2 diabetes patients, has been linked to an increased risk of bladder cancer. As a result, the US Food and Drug Administration (FDA) is requiring the drug’s manufacturer, Takeda, to include this risk on the labeling for Actos.
The FDA’s review of an ongoing study conducted by Takeda showed a 40 percent increase in risk for patients who had been taking Actos for a year or longer. The study also showed an increased risk for people who take the highest doses of Actos.
People taking low doses of the drug for less than a year did not show a greater risk than people not taking the drug.
Bladder cancer is a serious and fatal disease. The symptoms of bladder cancer include:
• Blood in your urine
• Frequent urination
• Painful urination
• Frequent urge to urinate
• Abdominal and back pain
If you are diagnosed with bladder cancer, you will be facing steep medical expenses. Your life and the lives of your family members will be forever altered by the presence of this disease.
If you have developed bladder cancer since taking Actos, please contact the experienced Milwaukee, Wisconsin dangerous drug attorneys at Cochran Firm Wisconsin to schedule a consultation.
Complications of Transvaginal Surgical Mesh
In September, 2011, an advisory panel and the FDA agreed to increase transvaginal mesh risk from moderate to high and to require further research into the procedure’s safety and effectiveness.
In the past, the FDA indicated that there are complications associated with transvaginal mesh and that these complications are not rare. Complications of the procedure include:
• Bladder perforation
• Bowel perforation
• Blood vessel perforation
• Pelvic hemorrhage
• Urinary incontinence
• Pain during sex
• Mesh erosion
• Abdominal and vaginal pain
This seemingly defective medical device can severely alter and affect a woman’s life, and yet it continues to be a popular treatment for women with pelvic organ prolapse (POP) and stress urinary incontinence (SUI). According to the FDA, there were 100,000 cases of POP treated with surgical mesh in 2010, and 75 percent of those cases were performed transvaginally.
The transvaginal placement of surgical mesh is high-risk. According to the FDA, there were 3,000 reports of complications from 2008 to 2010, more than double the number reported for the years 2005 to 2007.
If you have suffered from the complications of transvaginal mesh in Milwaukee, Wisconsin, or the surrounding areas, please contact the experienced defective medical device attorneys at the Cochran Firm Wisconsin to schedule a consultation.